Erratum to: Diabetes Ther DOI 10.1007/s13300-015-0100-8
In the Introduction, the sentence “The IDF guidelines recommend starting with a long-acting basal insulin analog, with pre-mixed insulin for those with higher HbA1C” should read:
“The IDF guidelines recommend starting with a long-acting basal insulin, and suggest starting with pre-mixed insulins for those with a higher starting HbA1C.”
The Conflict of interest section should read:
Manish Khanolkar has consulted in an advisory capacity and recieved speaker’s fees for Eli Lilly, Sanofi Aventis and Novo Nordisk. Shekhar Sehgal declares that he has no conflict of interest.
Open Access
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s13300-015-0100-8.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Sehgal, S., Khanolkar, M. Erratum to: Starting Insulin in Type 2 Diabetes: Real-World Outcomes After the First 12 Months of Insulin Therapy in a New Zealand Cohort. Diabetes Ther 6, 99 (2015). https://doi.org/10.1007/s13300-015-0102-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13300-015-0102-6